Loading...
XNAS
GTBP
Market cap6mUSD
Dec 05, Last price  
0.61USD
1D
-3.24%
1Q
-35.51%
IPO
-99.98%
Name

GT Biopharma Inc

Chart & Performance

D1W1MN
XNAS:GTBP chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
75.85%
Rev. gr., 5y
%
Revenues
0k
2,497,0005,776,0006,049,0001,143,00048,00011,00026,000342,000368,00061,00027,000000000000
Net income
-13m
L+73.25%
-3,109,000-4,940,000471,000-5,006,000-2,246,000-2,995,000-3,700,000-5,171,000-501,000-23,489,000-32,726,00021,033,000-143,247,000-259,186,000-40,775,000-31,616,000-58,693,000-20,503,000-7,597,000-13,162,000
CFO
-13m
L+45.77%
-2,093,000-671,000-270,000-169,000-937,000-1,535,000-963,000-987,000-442,000-1,749,000-4,657,000-1,930,000-5,430,000-10,677,000-3,659,000-7,262,000-15,606,000-15,217,000-8,852,000-12,904,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
URL
https://www.gtbiopharma.com/
IPO date
Oct 22, 2013
Employees
2
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT